CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced the results of its randomized, placebo controlled, multi-center “Proof of Concept” (POC) trial that was initiated to investigate the potential for its novel, ‘once a day’ combination product for the treatment of seasonal allergic rhinitis (SAR) to meet its desired endpoints. The approved commercially available components of the product candidate were used for this trial.
